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collection of phenotype data and other per-
sonal information through web-based surveys, 
in order to perform genome-wide association 
studies (GWAS).3 In March 2012, 23andMe 
reported having DNA data for approximately 
200 000 customers (with nearly 90% having 
opted in to participate in research), and more 
than 90 million individual survey responses or 
‘phenotypic data points’.4 An earlier announce-
ment by 23andMe stated that from a total of 
about 100 000 customers, around 76% agreed 
to participate in research.5 Fifty-nine percent 
of research participants provided responses to 
23andMe’s online questionnaires, with those 
taking surveys filling out at least 10 surveys 
on average. 
23andMe’s research is conducted through its 
research arm, 23andWe, as well as its recently 
launched 23andMe Research Portal. 23andWe 
is described as a customer-driven, web-based 
collaborative research study undertaken by 
23andMe’s internal investigators.6–8 On the other 
hand, the 23andMe Research Portal is offered 
as a research platform to external investigators 
or third-party researchers who wish to access 
23andMe’s database of genotype information 
and other data. Individuals who wish to have 
their DNA genotyped pay a fee of US$99 and, 
H
ere, online initiatives by two private 
companies, 23andMe and PatientsLikeMe, 
that utilise a system of dynamic consent 
for the collection and use of a large volume of 
health and medical data, are discussed. Based 
on the overseas projects discussed in these two 
online initiatives and the projects discussed in 
the first article, a description of the essential 
characteristics for the new and evolving concept 
of dynamic consent will be offered. In addition, 
new possibilities as well as limitations will be 
noted. Of particular interest for the New Zealand 
context is the question of how dynamic consent 
will fit in with the local regulatory framework 
for informed consent. There is potential for 
dynamic consent to be adopted in New Zealand 
to build on key elements of informed consent and 
help foster respect for the rights and interests of 
patients and research participants.
Online initiatives utilising the 
dynamic consent approach
23andMe
23andMe is a web-based private company that 
sells direct-to-consumer DNA testing services 
online.2 The company’s research platform in-
corporates web-based recruitment, and involves 
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based on the genotyping carried out, they receive 
personalised reports relating to their health, 
ancestry and traits.9 At the same time, they are 
asked to participate in genetic research that would 
involve completing online surveys relating to 
their health and lifestyle. Besides recruiting cus-
tomers into research, the company has attracted 
eligible individuals to participate in research by 
waiving the fee that would normally be charged 
for personal genotyping services, in exchange 
for their participation in any of its four research 
initiatives. The research initiatives relate to 
Parkinson’s disease, sarcoma, myeloproliferative 
neoplasms, and ‘Roots into the Future’, which 
is a research project aimed at recruiting 10 000 
American adult participants of African descent 
for the investigation of the connection between 
DNA and disease.
Enrolment, participation and ongoing engage-
ment in 23andMe’s research take place in an 
interactive web-based environment and includes 
the following steps.10,11,12 An individual who 
signs up to 23andMe via the web is sent a col-
lection kit so that a sample can be provided. The 
individual needs to visit the company’s website 
to set up or finalise a personal online account, 
and then register the unique barcode number of 
the collection kit. While logged in, the indi-
vidual is presented with the company’s Terms of 
Service (ToS) which set out the legal basis for the 
genotyping services offered that will involve the 
extraction and processing of DNA, the upload-
ing of a digital version of the individual’s genetic 
information on 23andMe’s website, as well as the 
creation and sharing of content on the company’s 
website. After the ToS has been accepted, the 
online system asks the individual to consent 
to 23andMe’s research activities. Besides that, 
the system offers an option for biobanking the 
sample supplied by the customer or research 
participant. (The terms ‘customer’ and ‘research 
participant’ are used very specifically here to 
indicate the differing circumstances and nature 
of relationship between the individual and the 
company where, as part of a contractual trans-
action, the individual has paid a fee in return 
for genotyping through the company’s Personal 
Genome Service®, or where the individual has re-
sponded to any online invitation by the company 
to participate in research.)
During the time that the sample is analysed by 
23andMe, the individual is presented with invita-
tions to participate in research surveys. When 
the personal genetic data (comprising both raw 
genotypes and customised reports) are available, 
the individual is notified by email to log on to 
the service website; as well, additional invitations 
are extended to the individual to participate in 
further surveys. After this point, the individual 
continues to receive new genetic reports and new 
surveys. The continuous two-way interaction be-
tween the individual and company is maintained 
online with the individual choosing whether to 
further participate, and if so, what other surveys 
to complete. This kind of interactive consenting 
process has been observed as having:
the obvious benefit that it reduces the bureaucratic 
burden of re-contact and re-consent while at the 
same time, enabling the participants to exercise 
their autonomy by giving informed consent for new 
research.13 
The ability to withdraw from 23andMe’s research 
can be exercised at any time, whenever the 
individual chooses to do so.6 Withdrawal from 
research does not affect the individual’s access to 
genetic information or ongoing use of services 
provided by the company, which continues to 
generate and make available new reports about 
latest discoveries.
An important point must be noted. 23andMe 
states that even if individuals do not give con-
sent for their information to be used in research 
relating to 23andWe or the 23andMe Research 
Portal, their ‘genetic and/or self-reported infor-
mation’, which may include identifiable infor-
mation, may still be used by the company for 
‘R&D’ purposes.14 R&D is defined by 23andMe 
as ‘research and development activities performed 
by 23andMe on user data’.14 23andMe states 
that such activities ‘may include, among other 
things, improving [23andMe’s] services and/or 
offering new products or services to [custom-
ers or participants]; performing quality control 
activities; conducting data analysis that may lead 
to and/or include commercialisation with a third 
party’.14 The breadth of such R&D activities 
should be carefully noted by potential customers 
or research participants.VOLUME 5 • NUMBER 4 • DECEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE 343
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PatientsLikeMe
PatientsLikeMe (PLM) is a health data-sharing 
platform that incorporates social networking 
functions. PLM enables an online peer support 
community of patients to connect and share 
information about their medical conditions, 
health status and general wellbeing.15 PLM has 
been described as ‘extend[ing] the functionality 
of traditional qualitative online patient communi-
ties to encompass quantitative patient-reported 
data’.16 Using crowdsourcing methods since it was 
launched in March 2006,17 PLM has been devel-
oping its repository of health information that, to 
date, includes over 177 000 individuals and more 
than 1000 conditions.18 With the large database 
of information, PLM has developed a pioneering 
model of conducting online health research.15 
PLM is not, strictly speaking, a research biobank 
and does not have responsibilities nor provide 
facilities for storing samples. However, where 
individuals have test results from having their 
DNA analysed, they can opt to have their genetic 
information uploaded, entered into their online 
profile and made ‘findable’ by others who share 
the same genetic characteristics.19
The individuals who sign up as members of PLM’s 
online community usually have chronic, life-
changing diseases. They find others like them, 
matched on demographic and clinical characteris-
tics, and share information about their diagnoses. 
Members provide self-reported data on treatments, 
symptoms and health outcomes. PLM enables 
them to enter their data for retrieval by others, 
track their own health condition and interact with 
other members, whether one-on-one through 
private messages, or as a group in an online forum, 
regardless of location or time of day. Members 
can gain information from the aggregated data 
reports of others with a view to improve their 
own outcomes.16 While similar sites offer patients 
the online ability to communicate and support 
each other, PLM is unique in the way it prompts 
members to enter data and employs a range of 
web-enabled tools to display that data, to provide 
actionable information.20 PLM states that it aims 
to improve quality of life by facilitating informa-
tion sharing and helping patients answer the ques-
tion: ‘Given my status, what is the best outcome I 
can hope to achieve, and how do I get there?’16
Significantly, PLM is a key international social-
networking site, with a real-time research 
platform. PLM and its collaborators conduct 
their own non-traditional research by collecting 
and analysing data on the site. PLM has its own 
research and development team that conducts 
studies that may be pursued in partnership 
with clinical, academic, industry or commercial 
researchers.21 Furthermore, members can research 
their own medical questions and they are given 
options to share structured, detailed and longi-
tudinal medical information with one another, 
and to discuss that information online.22 They 
can input a range of data, such as their condition, 
treatment history, side effects, hospitalisations, 
symptoms, disease-specific functional scores, 
weight, mood and quality of life on an ongoing 
basis. In effect, longitudinal patient-maintained 
records of health data can be constructed online. 
With PLM’s software, the data can be reported 
back as individual-level graphical health profiles, 
and aggregated into reports to help patients gain 
insight and identify patterns.
Of primary interest here is the way in which 
individuals participate and choose to supply their 
information to PLM. Participation in PLM’s 
community involves information sharing and 
interactive communication that can be regarded 
as taking place in a dynamic manner. The health 
history profiles of individuals are shared within 
the site with other members, and data are also 
automatically aggregated from all members in the 
community, to create summaries of treatments 
and symptoms.22 PLM’s search and browsing 
tools help individual members to locate others 
with shared medical experiences and in similar 
circumstances. Members have the ability to track 
the use of their data. In addition, because PLM 
incorporates real-time listings directly from 
ClinicalTrials.gov, members can learn about re-
search findings that are being publicised, as well 
as search for trials for which they may be eligible 
to participate based on their age, sex, condition 
and location.23 (ClinicalTrials.gov is open access 
and free of charge. It is the largest database in 
the world for publicly and privately supported 
clinical trials, with current registrations from 
more than 139 000 studies in 182 countries). At 
any time, members can cancel or permanently 
deactivate their account.24,25344  VOLUME 5 • NUMBER 4 • DECEMBER 2013  JOURNAL OF PRIMARY HEALTH CARE
Dynamic consent: general discussion
The meaning of dynamic consent has evolved in 
step with changing technological developments 
over the past decade. It can be described as en-
compassing a range of characteristics that enable 
interactive ways for individuals to express and 
change their consent virtually immediately, at 
any time, and on a continuous or ongoing basis. 
In other words, individuals are not restricted to 
static, one-off, unchanging or time-consuming 
ways that permit only single or very limited 
abilities to indicate or modify their preferences. 
With dynamic consent, individuals can exercise 
greater control over their information or samples 
in real time. They can make choices that can be 
modified at another time. They are able to specify 
their privacy preferences, for example, by indicat-
tinuous basis. They can protect and manage their 
privacy through the dynamic consent interface, 
by using online tools that allow them to choose 
privacy settings in line with their privacy prefer-
ences. The ability to have the technological means 
to maintain ongoing engagement with patients 
or participants provides a significant advantage 
where it is necessary or desirable to re-contact 
them; for example, to obtain new consent, collect 
additional information, communicate research 
results or disclose incidental findings. Thus, there 
is considerable potential for dynamic consent 
mechanisms to strengthen long-term therapeutic 
relationships with patients, as well as to develop 
ongoing research partnerships with participants.
Dynamic consent exercised through the electron-
ic or online system marks a paradigmatic change 
Dynamic consent… has evolved in step with changing technological 
developments over the past decade. It can be described as 
encompassing a range of characteristics that enable interactive 
ways for individuals to express and change their consent virtually 
immediately, at any time, and on a continuous or ongoing basis.
ing that they agree for their information or sam-
ples to be used, transferred to third parties, or 
that they wish to receive notifications in relation 
to any uses or disclosures of their information or 
samples. They may change their initial settings, 
as well as continue to express or change their 
choices over time, or even revoke their consent or 
previously expressed preferences. They can also 
track and audit any changes made, and indicate 
when and how they are to be contacted.26,27 
Health care professionals need to foster a rela-
tionship of confidence, trust and understanding 
so that there is real insight into whether or not 
the patient or participant fully grasps what is at 
stake.28 At the heart of dynamic consent are mech-
anisms that enable communication to and from 
patients or participants over time, hence offering 
them the opportunity to remain informed and in 
control of their information or samples on a con-
from the paper-based system of obtaining con-
sent. Paper-based consent has been predominantly 
focused on the one-off, unidirectional format of 
communicating and providing information, and is 
static in the sense that the interaction is confined 
to a defined single study or situation.29 Addition-
ally, it has been said that traditional paper-based 
consent:
is given and is only revoked by determined indi-
viduals who are able to make their way through the 
(rarely used) mechanisms for withdrawal.30
However, while technological developments and 
innovations create new ways to do things differ-
ently, there are implications and limitations that 
should be identified or recognised. Disparities 
in accessing information and communication 
technologies exist among different demographic, 
socioeconomic and geographic groups, such as 
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the elderly, people with disabilities, low-income 
families, and isolated or rural communities. The 
practical implementation of dynamic consent 
mechanisms, being dependent on both computers 
and the internet, introduces issues that are not 
just technical or technological but raises concerns 
that are essentially ethical in nature, relating to 
the ‘digital divide’.
Regulatory considerations 
in New Zealand
How do the various models of dynamic consent 
described in this article fit in with the regula-
tory framework for informed consent in New 
Zealand? This is a question relevant to those in 
New Zealand who are considering designing or 
trialling dynamic consent. This may include, for 
instance, those looking to support the develop-
ment of personalised medicine, or to strengthen 
engagement with participants in human tissue 
research, as well as those considering innovative 
initiatives in primary health care. The feasibility 
of a dynamic consent model for long-term, ongo-
ing, multiple uses of human tissue, for different 
types of genomics research, is currently being ex-
plored by the principal author with collaborators 
associated with the international and multidisci-
plinary University of Otago’s Centre for Society, 
Governance & Science (SoGoS) that is led by the 
Faculty of Law, University of Otago.
A brief, general overview of the health regulatory 
framework for informed consent to be obtained 
from individuals in New Zealand can be stated 
as follows. The New Zealand Bill of Rights 1990 
upholds the right to refuse to undergo any medi-
cal treatment and the right not to be subjected 
to medical or scientific experimentation without 
the person’s consent.31 The law in New Zealand 
enshrines the principle that informed consent is 
required prior to any ‘health care procedure’ being 
performed on an individual.32,33 Informed consent 
is required, except where any enactment or any 
provision of the Code of Health and Disability 
Services Consumers’ Rights33 provides otherwise. 
The definition of ‘health care procedure’ is wide 
and encompasses health treatment, examina-
tion, teaching or research, and extends to any 
provision of health services.32 For the collection, 
storage, use and disclosure of health information, 
appropriate authorisation needs to be obtained in 
accordance with the rules of the Health Informa-
tion Privacy Code 1994.34 For human samples 
removed or obtained in the course of a health care 
procedure, the general rule (subject to exceptions) 
is that they must be stored, preserved or used 
with the consent of that individual, or a person 
entitled to consent on behalf of that individual.33 
In the context of health research, an exception 
is provided for the samples to be used without 
consent, if the proposed research has been ap-
proved by an ethics committee or, in other words, 
if the committee grants a waiver to the researcher 
from the requirement to seek informed consent.33 
Approval needs to be given by an appropriately 
constituted ethics committee that, in the main, 
has been accredited or approved by the Health 
Research Council Ethics Committee.
However, even though ethics committees have 
been vested with power to grant such a waiver, 
the law is silent on the circumstances as to when 
ethics committees may exercise the discretion to 
do so, or as to the conditions, criteria or factors 
that have to be taken into account. The Health 
Research Council’s Guidelines on Ethics in Health 
Research indicate that requests for waivers can 
be sought from ethics committees if researchers 
consider it is:
impossible, impractical or excessively costly to 
obtain consent, or that doing so would adversely 
affect the outcome of the [proposed] research.35
While those four grounds may seem clear 
enough, it will be a matter for ethics committees 
to determine, depending on the factual circum-
stances and details of the specific research pro-
posal, whether any of those grounds have been 
met, as well as what additional safeguards should 
be in place. Documented instances of waiv-
ers being granted are rare, but not unknown.36 
In addition, the use of human tissue for future 
unspecified research purposes in New Zealand is 
regulated by Ministry of Health guidelines that 
specify the circumstances and conditions under 
which researchers have to obtain consent from 
individuals for such research to be undertaken.37
The dynamic consent system can be viewed 
as introducing significantly new and different 
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technology-enabled mechanisms that have the 
ability to improve the informed consent process. 
The key elements of informed consent comprise:
1.  communication between the health 
professional or researcher and the individual;
2. provision of adequate information to the 
individual; and
3.  meaningful opportunity for the individual to 
exercise informed choice and consent.
These three elements are encapsulated in rights 5, 
6 and 7 of the Code of Health and Disability Ser-
vices Consumers’ Rights, respectively.33 Dynamic 
consent builds on each of these elements and, in 
its entirety, may have the potential to transcend 
the conventional bounds of the process of obtain-
ing informed consent and may help foster deep 
respect for the rights and interests of patients and 
participants. 
As discussed, the dynamic consent approach 
is specifically characterised by continuity and 
high interactivity, thus marking a significant 
change from the one-off, unidirectional format 
of communicating and providing information. 
With dynamic consent, individuals can have a 
greater degree of control over the uses of their 
information or samples. The dynamic consent 
system makes it possible, practical and affordable 
to re-contact individuals. Interestingly, adoption 
of the dynamic consent approach might mean 
that it would be less relevant or necessary to seek 
waiver of consent in many instances. Addition-
ally, it may well be less essential to seek consent 
for future unspecified research because contact 
can be made with individuals to convey informa-
tion to them as, and when, details of any research 
become known, and they can then exercise their 
informed choice and decision whether to be 
involved.
Conclusion
The internet is inherently interactive, and it is 
from such an environment that dynamic con-
sent initiatives have emerged. Dynamic consent 
mechanisms give individuals the ability to 
consent and exercise greater control over their 
information or sample, as well as the choice to 
indicate or modify their future preferences with 
regards to consent. The use of such mechanisms 
can contribute to robust, transparent and effec-
tive processes, crucial for building the confidence 
and trust of patients or research participants. In 
the past decade, projects involving individuals 
from academia and private companies overseas, 
particularly in the US and the UK, have been 
initiated, and a diverse range of dynamic consent 
approaches and models have been adopted.
Looking ahead, there is considerable potential for 
dynamic consent systems to advance further and 
to be used more widely for online health services 
and research. While the current legal framework 
allows and does not hinder the continuing devel-
opment of dynamic consent, underlying challeng-
es surrounding the digital divide and accessibility 
to information and communication technologies 
remain. These issues are not just technical or 
technological but raise concerns that, ultimately, 
are ethical in nature and need to be addressed.
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